Compare medicines
Put up to three medicines side by side. Useful for alternatives in the same class, or for seeing how two very different treatments differ.
| Attribute | ||
|---|---|---|
| In short | PD-L1 checkpoint inhibitor given by infusion. | Immunotherapy for many cancers — the world's top-selling medicine. |
| Body system | Cancer | Cancer |
| Drug class | Immune checkpoint inhibitors | Immune checkpoint inhibitors |
| Supply | Prescription only | Prescription onlyWHO essential medicine |
| Main uses | Non-small-cell and small-cell lung cancer, Urothelial (bladder) cancer, Liver cancer (with bevacizumab) | Melanoma, Non-small cell lung cancer, Kidney, bladder, head and neck cancers, Triple-negative breast cancer, Cervical and endometrial cancer |
| How it works | Helps the immune system attack cancer. | Takes the brakes off your immune cells so they can find and kill cancer. |
| Starts working | Depends on the cancer and regimen | — |
| Half-life | About 27 days | About 22 days |
| Typical adult dose | Dosed by your cancer team according to the treatment protocol. | 200 mg every 3 weeks or 400 mg every 6 weeks IV. |
| Forms | IV infusion | IV infusion, Subcutaneous injection |
| Common side effects | Tiredness, Rash, Nausea, Cough, Loss of appetite | Tiredness, Rash and itch, Diarrhoea, Underactive thyroid |
| Serious side effects | Immune-related colitis, hepatitis, pneumonitis, thyroid and adrenal problems, Infusion reactions | Pneumonitis, Colitis, Hepatitis, Type 1 diabetes, Myocarditis, Adrenal or pituitary failure |
| Don't take if | Active serious autoimmune disease (caution); Pregnancy | — |
| Alcohol | Usually no problem in moderation. No specific interaction. | — |
| Pregnancy | Usually avoidedCan harm a developing baby. Effective contraception is advised during and after treatment. | Usually avoidedContraception needed. |
| Breastfeeding | Usually avoidedAvoid breastfeeding during treatment. | — |
| In use since | — | 2014 |
| Brand names | United States: TecentriqUnited Kingdom: TecentriqIndia: Tecentriq | United States: Keytruda, Keytruda QlexUnited Kingdom: KeytrudaIndia: Keytruda |
| Legal status | United States: Prescription onlyUnited Kingdom: Prescription-only medicine (POM), hospital useIndia: Schedule H | — |
| ATC code | L01FF05 | L01FF02 |
Taken together
No interaction between these medicines is recorded in the atlas.
Open in the interaction checker